Is Eloralintide the Next Ozempic?
It’s not a GLP-1 drug. It may be better than one.
Millions of people are on GLP-1 drugs. A lot of them don’t know that roughly 25 to 40 percent of the weight they’re losing comes from lean tissue, including muscle. Some of what you lose is the muscle you spent years working your ass off in the gym for.
That’s not a reason to stop using these drugs if you need them. But it’s a good idea to understand what’s happening in your body, and to know that a different class of compounds is emerging that appears to address the problem.
The compound is eloralintide. It’s a selective amylin receptor agonist developed by Eli Lilly. Eloralintide doesn’t work on the GLP-1 receptor at all. It works through amylin receptors, a pathway that traditional GLP-1 drugs do not directly target. Phase 2 data published in The Lancet in 2025 showed up to 20% body weight loss, comparable to tirzepatide. Preclinical findings suggest eloralintide may preserve lean mass more favorably during weight loss.
In the full version you’ll get:
The breakdown of every GLP-1 generation and the muscle preservation issue
The amylin signaling pathway, how it differs from GLP-1, and why those differences change the longevity calculation
The combination potential with existing GLP-1 protocols and what Lilly’s trial data suggests
Why eloralintide might be the next best thing
[Subscribe to unlock the full article]
